Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies.
Acute myeloid leukemia
Chronic myelomonocytic leukemia
Myelodysplastic syndrome
Phase I
Volasertib
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
21 May 2022
21 May 2022
Historique:
received:
13
01
2022
accepted:
29
04
2022
entrez:
21
5
2022
pubmed:
22
5
2022
medline:
25
5
2022
Statut:
epublish
Résumé
This report summarizes three phase I studies evaluating volasertib, a polo-like kinase inhibitor, plus azacitidine in adults with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia. Patients received intravenous volasertib in 28-day cycles (dose-escalation schedules). In Part 1 of 1230.33 (Study 1; NCT01957644), patients received 250-350 mg volasertib on day (D)1 and D15; in Part 2, patients received different schedules [A, D1: 170 mg/m Overall, 22 patients were treated (17 with MDS; 12 previously untreated). Across Studies 1 and 2 (n = 21), the most common drug-related adverse events were hematological (thrombocytopenia [n = 11]; neutropenia [n = 8]). All dose-limiting toxicities were grade 4 thrombocytopenia. The only treated patient in Study 3 experienced 18 adverse events following volasertib monotherapy. Studies 1 and 2 showed preliminary activity (objective response rates: 25 and 40%). The safety of volasertib with azacitidine in patients with MDS was consistent with other volasertib studies. All studies were terminated prematurely following the discontinuation of volasertib for non-clinical reasons by Boehringer Ingelheim; however, safety information on volasertib plus azacitidine are of interest for future studies in other diseases.
Sections du résumé
BACKGROUND
BACKGROUND
This report summarizes three phase I studies evaluating volasertib, a polo-like kinase inhibitor, plus azacitidine in adults with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia.
METHODS
METHODS
Patients received intravenous volasertib in 28-day cycles (dose-escalation schedules). In Part 1 of 1230.33 (Study 1; NCT01957644), patients received 250-350 mg volasertib on day (D)1 and D15; in Part 2, patients received different schedules [A, D1: 170 mg/m
RESULTS
RESULTS
Overall, 22 patients were treated (17 with MDS; 12 previously untreated). Across Studies 1 and 2 (n = 21), the most common drug-related adverse events were hematological (thrombocytopenia [n = 11]; neutropenia [n = 8]). All dose-limiting toxicities were grade 4 thrombocytopenia. The only treated patient in Study 3 experienced 18 adverse events following volasertib monotherapy. Studies 1 and 2 showed preliminary activity (objective response rates: 25 and 40%).
CONCLUSIONS
CONCLUSIONS
The safety of volasertib with azacitidine in patients with MDS was consistent with other volasertib studies. All studies were terminated prematurely following the discontinuation of volasertib for non-clinical reasons by Boehringer Ingelheim; however, safety information on volasertib plus azacitidine are of interest for future studies in other diseases.
Identifiants
pubmed: 35597904
doi: 10.1186/s12885-022-09622-0
pii: 10.1186/s12885-022-09622-0
pmc: PMC9124414
doi:
Substances chimiques
BI 6727
0
Pteridines
0
Azacitidine
M801H13NRU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
569Subventions
Organisme : Boehringer Ingelheim
ID : N/A
Informations de copyright
© 2022. The Author(s).
Références
J Clin Oncol. 2002 May 15;20(10):2429-40
pubmed: 12011120
Blood. 2019 Mar 7;133(10):1096-1107
pubmed: 30670446
Blood. 2014 Aug 28;124(9):1426-33
pubmed: 25006120
J Clin Oncol. 2006 Aug 20;24(24):3895-903
pubmed: 16921040
Br J Haematol. 2019 Mar;184(6):1018-1021
pubmed: 29882583
Ann Oncol. 2014 Sep;25 Suppl 3:iii57-69
pubmed: 25185242
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
Cancer Sci. 2015 Nov;106(11):1590-5
pubmed: 26471242
Hemasphere. 2018 Nov 29;2(6):e150
pubmed: 31723789
Blood. 2015 Jul 16;126(3):291-9
pubmed: 25987659
Clin Epigenetics. 2016 Jun 21;8:71
pubmed: 27330573
J Pharmacol Exp Ther. 2015 Mar;352(3):579-89
pubmed: 25576074
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Ann Hematol. 2018 Nov;97(11):2025-2038
pubmed: 30084010
Clin Cancer Res. 2009 May 1;15(9):3094-102
pubmed: 19383823
Ther Adv Hematol. 2019 May 09;10:2040620719847059
pubmed: 31156799